Source: The Business Journals

Sarepta Therapeutics: Biotech firm makes $2.8B deal to license muscular dystrophy gene therapy

A gene therapy invented at Nationwide Children's Hospital just landed a licensing deal worth as much as $2.8 billion for a Boston biotech, and now the company's Columbus, Ohio office will play a big role in getting the treatment to the market. Sarepta Therapeutics Inc. has licensed the commercial rights outside of the United States to the Swiss pharmaceutical giant Roche for $1.1 billion in cash and stock up front. Sarepta also can earn as much as $1.7 billion in milestone payments, plus royalties....

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Based on data from Sarepta Therapeutics's latest SEC filings

Annual Revenue

Based on data from Sarepta Therapeutics's latest SEC filings

Employees

Douglas S. Ingram's photo - President & CEO of Sarepta Therapeutics

President & CEO

Douglas S. Ingram

CEO Approval Rating

89/100

Sarepta develops and commercializes ribonucleic acid targeted therapeutics for the treatment of neuromuscular diseases.

S...
Read more